Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
Discovery Medicine
|
March 1, 2015
Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome
Rishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine
|
March 1, 2015
Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies
Rishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine
|
January 1, 2015
Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome
Rishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Nature
|
April 11, 2014
Copper is required for oncogenic BRAF signalling and tumorigenesis
Donita C Brady, Matthew S Crowe, Michelle L Turski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2026
Efficacy of the ATR inhibitor ceralasertib in patients with ARID1A-deficient gynecologic and other solid tumor malignancies
Xiaolin Zhu, Edwin A Alvarez, Sarah E Umetsu, et al.
The Oncologist
|
June 22, 2024
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains
Xiaolin Zhu, Emily Chan, Michelle L Turski, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
Discovery Medicine
|
March 1, 2015
Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome
Rishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine
|
March 1, 2015
Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies
Rishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine
|
January 1, 2015
Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome
Rishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Nature
|
April 11, 2014
Copper is required for oncogenic BRAF signalling and tumorigenesis
Donita C Brady, Matthew S Crowe, Michelle L Turski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2026
Efficacy of the ATR inhibitor ceralasertib in patients with ARID1A-deficient gynecologic and other solid tumor malignancies
Xiaolin Zhu, Edwin A Alvarez, Sarah E Umetsu, et al.
The Oncologist
|
June 22, 2024
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains
Xiaolin Zhu, Emily Chan, Michelle L Turski, et al.
Page
of 2